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Background: Juglans regia L. (J. regia ) is one of the medicinal plants traditionally used for treatment of diabetes
in Iranian medicine. The effect of this plant has already been investigated on animal models; however, this is the
first study conducted on human subjects. The aim of this study is to investigate the hypoglycemic effect of J. regia
leaves aqueous extract in type 2 diabetes patients. Fifty eight Iranian male and female patients with type 2 diabetes
were enrolled. The patients were randomly allocated into two groups. One group (n = 30) received J. regia leaves
extract while the other group (n = 28) received placebo. Fasting blood samples were collected at the beginning of
the study and after two months for determination of HbA1c and blood glucose level as a main outcome and
insulin, SGOT, SGPT, and ALP level as secondary outcome.
Results: Our analysis showed that serum fasting HbA1C and blood glucose levels were significantly decreased and
the insulin level was increased in patients in the J. regia arm.
Conclusions: The results indicate that J. regia aqueous extract favorably affects blood levels of glucose, insulin and
HbA1C in type 2 diabetic patients.
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Diabetes mellitus is a major public health problem in both
developed and developing countries. Among the leading
causes of death, diabetes mellitus is ranked seventh and
when fatal complications are taken into the account, it is
ranked third [1]. Recently, there has been increasing inte-
rest in the use of medicinal plants. Frequently, however, it
is mandatory to provide scientific proof in order to justify
the use of a plant or its active components [2]. Several
studies confirm the potential therapeutic efficacy of some
medicinal plants in treatment of diabetic patients [3]. Since
natural products may provide better treatments with fewer
side effects than the existing artificial medications, a major
focus for suitable anti-hyperglycemic agents has been
on plants used in traditional medicine [4]. The probable* Correspondence: jamshidi.nutrition@yahoo.com
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reproduction in any medium, provided the orefficiency of medicinal plants for treating diabetes and
their abundance in most parts of the world facilitate their
usage. J. regia belongs to the family Juglandaceae. It in-
cludes 3 species: J. nigra, J. cinerea, and J. regia although
only J. regia type is found in Iran [5]. Investigations show
that J. regia extract contains ellagitannins which contains
anti-cancer agent and with anti-inflammatory properties
[6]. The key chemical composition of walnut is Juglone
(5-hydroxy-1,4-naphthoquinone), the toxic compound
which is found only in green and fresh walnuts, but such
property disappear in dried leaves [7]. Other several phe-
nolic compounds with antioxidant properties have been
identified in J. regia leaves [8]. In an experimental study
treatment of J. regia extracts in experimental animals re-
sulted in a significant decrease in blood glucose, glyco-
sylated hemoglobin, LDL, triglyceride and total cholesterol
and a significant increase in insulin and HDL level [9]. In
another study the favorable effects of J. regia leaves on
pancreatic cells in alloxan induced diabetic rat have beenl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that fasting blood sugar decreased meaningfully where as
insulin level increased and glycosylated hemoglobin de-
creased significantly in diabetic groups receiving either
glibenclamide or J. regia extract compared with the dia-
betic untreated group [11]. In the present study, we evalu-
ated the effect of J. regia leaves aqueous extract on type II
diabetic patients for the first time.
Methods
Plant material and extraction procedure
J. regia leaves were collected from institute of medicinal
plant Farm Karaj Iran. The leaves were washed by distilled
water and placed in oven at 37°C to dry. Then, the leaves
were completely pulverized using a porcelain mortar and
pester. The powder was soaked in distilled water and placed
on a magnetic stirrer for 24 hours to resolve completely.
The resulting solution was passed through a filter paper and
dried under appropriate conditions (in the oven at 37°C).
Participants
Initially, total of 62 patients (37 female and 25 male) with
type 2 diabetes were recruited through an announcementCONSORT 201
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Figure 1 The CONSORT flowchart describing the progress of the patiemade in the Diabetes Clinic of Shariati Hospital. The
patients were randomly divided into two equal groups
(J. regia and placebo). Shortly after the start of the
study, 4 patients withdrew for personal reasons and the
study continued with the remaining 58 patients (Figure 1)
including 35 female and 23 male. The research protocol
was approved by the Ethics Committee of the Endocri-
nology and Metabolism Research Center of Shariati
Hospital and written informed consent was obtained of
each patient prior to the study. All the patients who par-
ticipated were aged between 40 and 65 years and had a
confirmed diabetes type 2 diagnoses according to ADA
criteria [12]. The inclusion criteria were: age 30 to 80,
HbA1C > 7% fasting blood glucose less than 250 mg/L
and taking maximum dose of two anti- diabetic drug
(metformin and glibenclamide). The exclusion criteria
were: Immune deficiency, pregnancy and lactation, car-
diovascular disease, currently receiving corticosteroids
and thiazide, uncontrolled thyroid dysfunction, acute
infection, history of diabetic ketoacidosis, Cr > 1.5 for
male, Cr > 1.2 for female, acute hepatitis, cirrhosis,
proliferative retinopathy and severe weight loss (at least
10% during last 6 months).0 Flow Diagram
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nts through the trial.
Table 2 Para clinical characteristics of the two groups at
the beginning of the study (mean ± SD)
Groups
J. regia Placebo p-value
FBS (mg/dl) 165 ± 52 168 ± 65 0.82
HbA1c (%) 8.5 ± 1.6 8.3 ± 1.7 0.588
Insulin (ng/ml) 0.9 ± 0.7 0.7 ± 0.4 0.274
SGOT (U/L) 11.7 ± 5.3 12.5 ± 4.2 0.910
SGPT (U/L) 8.7 ± 3.7 9.5 ± 3.1 0.665
ALP (IU/L) 159 ± 34 151 ± 59 0.502
Table 1 The demographic characteristics of patients in
placebo and J. regia treated groups (mean ± SD)
Groups J. regia Placebo p-value
Age (year) 58.1 ± 4.2 56.2 ± 7.3 0.21
Sex (male/female) 11 M/19 F 12 M/16 F 0.69
Duration of disease (year) 5.2 ± 1.6 6.2 ± 1.1 0.006
Weight (kg) 62.3 ± 5.6 60.6 ± 6.1 0.52
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The patients were randomly allocated to two groups using
a balanced randomization method. The patients and in-
vestigators who carried out clinical and para-clinical as-
sessments were unaware of the treatment groups and
the type of medication. J. regia (100 mg) and placebo tab-
lets of the same shape were provided by the Institute of
Medicinal Plants (Tehran, Iran). The conventional oral
hypoglycemic agents (metformin and glibenclamide) con-
tinued in both groups. Compliance was assessed indirectly
using the pill count method. The first group (32 patients)
received one 200 mg J. regia tablet two times a day before
meal. Also, the control group (29 patients) received a pla-
cebo tablet twice a day before meal. The blood levels of
HbA1c and fasting blood glucose, insulin, SGOT, SGPT,
and ALP were measured at the beginning and after 2
months of the study in both groups. Blood samples were
drawn after overnight fasting (12 h). Fasting glucose levels
were measured using the gloucose-oxidase method using
a Beckman Glucose2 Analyzer immediately after blood
sampling at the Endocrine Research Center Laboratory.
Glycosylated hemoglobin levels were measured by a D-10
hemoglobin testing system (Bio-Rad Laboratories, Inc.).
All other blood sample parameters were measured by an
auto analyzer (Hitachi 902) using commercial kits. Pa-
tients were visited and examined every month and the effi-
cacy of treatment was checked by measurement of the
fasting blood glucose level. Sample size was calculated
comparing the main outcome of the study (namely FBS)
to detect 10 mg/dl of reduction from the baseline group
with 80% of power and 5% sig. level.
Statistical analysis
Paired sample t test was conducted for comparing the pre
and post evaluation and independent sample t test was
preformed to compare the differences between two groups.
Statistical analysis was carried on using R statistical pack-
age version3.0.1 (R Core Team 2013. R: A language and
environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria). A p-value less
than 0.05 was considered statistically significant (Figure 1).
Results
All 58 patients completed the study with no further
dropouts. The patients' demographic characteristics are
summarized in Table 1.
The baseline findings of patients in the two groups
(J. regia and placebo) were compared for FBS, HbA1c,
insulin and liver enzymes. The two groups were com-
pletely comparable regarding baseline and demographic
characteristics (Table 2).
The average fasting blood glucose level in the J. regia
group was 165 ± 54 mg /dL in the beginning of the study
which significantly decreased (p < 0.05) to 144 ± 65 mg /dLafter 2 months of treatment with J. regia. The average
fasting blood glucose level in the placebo group was not
significantly changed after 2 months of the study.
The average HbA1c level in the J. regia group at the
beginning of the study was 8.5 ± 1.6 mg /dL, which de-
creased significantly (p < 0.05) to 7.6 ± 1.3 mg /dL after 2
months of J. regia treatment. The average HbA1c level
in the placebo group was 8.3 ± 1.7 mg /dL at the begin-
ning of the study which decreased significantly (p < 0.05)
to 7.7 ± 1.5 mg /dL after 2 months of placebo treatment.
The average insulin level in the J. regia group was 8.6 ±
4.2 mg /dL in the beginning of the study which in-
creased significantly (p < 0.05) to 10 ± 4.7 mg /dL after 2
months of treatment with J. regia. The average insulin
level in the placebo group was not significantly changed
after 2 months of placebo treatment.
The results of the clinical findings in both groups in
the beginning and after 2 months of the study are sum-
marized in Table 3. Finally, No liver functional or other
gastrointestinal side effects of the treatment were re-
ported during the study.
Discussion
The results suggest that J. regia improves glycemic in
the type 2 diabetic patients without any adverse effects
on the kidney and hepatic function. The results showed
that although there were no significant differences in the
main parameters between the two groups of patients at
the beginning of the study, J. regia extract treatment sig-
nificantly lowered fasting blood glucose and HbA1c, and
increased the insulin level in diabetic patients at the end
Table 3 The serologic parameters in Placebo and J. regia treated groups (mean ± SD)
J. regia (n = 30) Placebo (n = 28)
Beginning After 2 month p-value Beginning After 2 month p-value P-value Difference of difference
FBS (mg/d L) 165 ± 54 144 ± 65 0.017 169 ± 71 171 ± 61 0.847 0.079
HbA1c (%) 8.5 ± 1.6 7.6 ± 1.3 0.000 8.3 ± 1.7 7.7 ± 1.5 0.042 0.068
Insulin (U/L) 8.6 ± 4.2 10.4 ± 4.7 0.007 8.6 ± 3.6 9.1 ± 3.9 0.413 0.138
SGOT (U/L) 11.6 ± 5.3 12.6 ±5.0 0.293 12.5 ± 4.2 12.2 ± 4.5 0.110 0.879
SGPT (U/L) 8.7 ± 3.7 9.7 ± 2.9 0.849 9.5 ± 3.1 8.5 ± 2.8 0.708 0.692
ALP (IU/L) 159 ± 30 163 ±43 0.469 152 ± 59 152 ± 46 0.228 0.660
HbA1c (%).
8.5% NGSP = 70 mmol/mol IFCC = 198 mg/dL eAG.
7.6% NGSP = 60 mmol/mol IFCC = 171 mg/dL eAG.
8.3% NGSP = 67 mmol/mol IFCC = 191 mg/dL eAG.
7.9% NGSP = 62 mmol/mol IFCC = 179 mg/dL eAG.
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ering effect of J. regia might be due to increase release
of insulin from remnant β-cells and/or regenerated β-
cells, restore insulin sensitivity [10], interference with the
absorption of dietary carbohydrates in the small intestine
[13], and facilitate utilization of glucose by peripheral tis-
sues mediated by an insulin dependent glucose transporter
[14]. The key compound responsible for antihyperglyce-
mic effect of the plant extract may be phenolic substances,
such as gallic acid and caffeoylquinic acid [15]. Phenolic
acids and flavonoids are two groups major phenolic com-
pounds existing J. regia leaves [8]. Caffeoylquinic acid and
acid coumaroylquinic are major phenolic acids in J. regia
leaves. The main flavonoids in walnut leaves are juglone,
quercetin 3-galactoside, quercetin 3-arabinoside, quer-
cetin 3-xyloside, quercetin 3-rhamnoside and quercetin
3-pentoside [16,17]. Histomorphologic studies conducted
in animal models of liver sections showed that the diabetic
group had moderate inflammation in the portal space, and
mild lobular necrosis was also observed where as in dia-
betic rats treated with the walnut extract, very mild portal
inflammation and inflammatory cells were seen without
any significant intra-lobular necrosis [18,19]. The same
study showed that in diabetic rats treated with walnut leaf
extract, serum AST and ALT had a significant decrease
when compared to diabetic rats. The decrease in the
plasma levels of AST and ALT is due to the decrease in
liver cells injury, glucose, cholesterol, triglyceride, hepatic
lipid levels and subsequently prevention from the forma-
tion of fatty liver. Our findings also indicated that treat-
ment with J. regia did not adversely affects SGOT and
SGPT levels as indication of its safety. In conclusion, our
finding showed that the use of J. regia leaves was effective
for glycemic control of diabetic patients. Since this study
was conducted on human samples for the first time, there-
fore the lowest dose of the drug was used. Considering the
hypoglycemic effect of J. regia leaves in present study and
to obtain better results, we suggest the efficacy of higher
doses investigated in future clinical trials.Competing interests
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